The latest data from a study show that Jardiance (empagliflozin) significantly decreases the chance of progressive kidney disease among adults who have both type 2 diabetes and cardiovascular disease.
As of today, the only SGLT2 inhibitor that shows kidney improvements with standard of care is Jardiance. This is thanks to the milestone EMPA-REG OUTCOME clinical trial that The New England Journal of Medicine recently published with Boehringer Ingelheim and Eli Lilly and Company.
"These findings are clinically important, given that more than a third of people with type 2 diabetes will develop kidney disease, which can lead to kidney failure and eventually the need for dialysis,” Dr. Christoph Wanner, chief of the Division of Nephrology and Hypertension at the University Hospital of Würzburg, Germany, said. “In the United States, the cost to treat chronic kidney disease is estimated to exceed $48 billion annually. Since diabetes is the number-one cause of kidney failure in the U.S., novel treatments that may have the potential to help address this crucial medical need are necessary."
In addition, Jardiance majorly slowed the decrease in kidney function that typically takes place over time. It showed significantly more benefits than the placebo in the trial.
"With these new EMPA-REG OUTCOME data, Jardiance is the only SGLT2 inhibitor associated with evidence of slowing the progression of kidney disease in adults with type 2 diabetes and established cardiovascular disease in a cardiovascular outcome study," Hans-Juergen Woerle, global vice president of medicine at Boehringer Ingelheim, said.
